Ascendis Pharma AS (ASND) Downgraded to “Hold” at Zacks Investment Research
Ascendis Pharma AS (NASDAQ:ASND) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Monday.
According to Zacks, “Ascendis Pharma A/S is a biopharmaceutical company. The company’s product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology, central nervous system disorders, infectious diseases and diabetes. Its technology includes TransCon which develop prodrug therapies. Ascendis Pharma A/S is based in Denmark. “
A number of other analysts have also issued reports on the stock. Wedbush started coverage on shares of Ascendis Pharma AS in a research note on Monday, September 26th. They set an “outperform” rating and a $34.00 target price for the company. TheStreet raised shares of Ascendis Pharma AS from a “sell” rating to a “hold” rating in a research note on Tuesday, September 6th. Finally, Leerink Swann reaffirmed a “buy” rating on shares of Ascendis Pharma AS in a research note on Friday, September 2nd.
Shares of Ascendis Pharma AS (NASDAQ:ASND) traded down 0.85% during mid-day trading on Monday, hitting $19.93. 6,930 shares of the stock were exchanged. The stock’s market cap is $502.10 million. Ascendis Pharma AS has a 12 month low of $11.92 and a 12 month high of $21.70. The stock’s 50 day moving average is $19.02 and its 200-day moving average is $16.14.
Ascendis Pharma AS (NASDAQ:ASND) last issued its earnings results on Wednesday, August 31st. The company reported ($0.59) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.69) by $0.10. On average, analysts anticipate that Ascendis Pharma AS will post ($3.14) EPS for the current year.
About Ascendis Pharma AS
Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop a pipeline of long-acting prodrug therapies that address markets with unmet medical needs. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.
Receive News & Stock Ratings for Ascendis Pharma AS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma AS and related stocks with our FREE daily email newsletter.